Akebia Therapeutics Inc (NASDAQ: AKBA) on Tuesday, plunged -5.08% from the previous trading day, before settling in for the closing price of $1.77. Within the past 52 weeks, AKBA’s price has moved between $0.80 and $2.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -10.63% over the last five years. The company achieved an average annual earnings per share of 43.18%. With a float of $250.51 million, this company’s outstanding shares have now reached $261.23 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is 60.08%, operating margin of -31.47%, and the pretax margin is -43.33%.
Akebia Therapeutics Inc (AKBA) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 23.96%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.18% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Akebia Therapeutics Inc (AKBA) is currently performing well based on its current performance indicators. A quick ratio of 1.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.33, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.02 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Analysing the last 5-days average volume posted by the [Akebia Therapeutics Inc, AKBA], we can find that recorded value of 4.18 million was better than the volume posted last year of 3.57 million. As of the previous 9 days, the stock’s Stochastic %D was 23.84%. Additionally, its Average True Range was 0.16.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 11.36%, which indicates a significant increase from 6.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 134.15% in the past 14 days, which was higher than the 90.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0157, while its 200-day Moving Average is $1.6779. Now, the first resistance to watch is $1.8100. This is followed by the second major resistance level at $1.9400. The third major resistance level sits at $2.0200. If the price goes on to break the first support level at $1.6000, it is likely to go to the next support level at $1.5200. Should the price break the second support level, the third support level stands at $1.3900.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
Market capitalization of the company is 438.87 million based on 236,231K outstanding shares. Right now, sales total 160,180 K and income totals -69,410 K. The company made 46,500 K in profit during its latest quarter, and -22,800 K in sales during its previous quarter.
